Michael S. Saporito, Ph.D.
Joined the team in 2017 as the President and CEO of Intervir. Dr. Saporito is a seasoned pharmaceutical entrepreneur, has over 28 years experience in the pharmaceutical industry, was co-founder and CSO of Melior Discovery, Inc., and held senior scientific positions at Cephalon and Locus Pharmaceuticals. Since 2015, Dr. Saporito has worked with a number of biopharmaceutical companies and venture groups providing expert input in translational research. Throughout his career Dr. Saporito has led efforts in the discovery and development of a number of clinical stage therapeutics.
Ronald N. Harty, Ph.D.
Dr. Harty is a Scientific Founder of Intervir and Professor of Pathobiology and Microbiology University of Pennsylvania School of Veterinary Medicine. Dr. Harty is a leading expert on mechanisms of virus budding/egress and virus-host interactions during virus replication. Intervir technology originated in Dr. Harty’s lab.
Bruce D. Freedman, VMD, Ph.D.
Dr. Freedman is a Scientific Founder of Intervir, Associate Professor of Pathobiology, and Director of the PennVet Imaging Core Facility in The School of Veterinary Medicine at the University of Pennsylvania. Dr. Freedman is an expert on host signaling mechanisms that regulate viral pathogenesis and host immune responses.
Jay Wrobel, Ph.D.
Dr. Wrobel leads the Intervir medicinal chemistry efforts. Jay has spent 28 years as a medicinal chemist in the pharmaceutical industry, 26 years at Wyeth (later Pfizer), with his last position as Senior Director of Medicinal Chemistry at the Collegeville, PA facility. At Wyeth he mentored and guided the efforts of 31 Ph.D./MS medicinal chemists and worked successfully with outside alliance partners. He was directly involved in bringing forward nine development track candidates (phase 0 and beyond) in a variety of therapeutic areas. He has co-authored 65 scientific publications and is an inventor on 75 issued US patents.
Allen B. Reitz, Ph.D.
Dr. Reitz will be co-lead on Intervir medicinal chemistry efforts. Dr. Reitz has >31 years of demonstrated accomplishment as a medicinal chemist in the pharmaceutical industry, including nearly 26 years with Johnson & Johnson. At Johnson & Johnson he led the medicinal chemistry research effort in the area of the diseases of the central nervous system . He is co-inventor as well as Team Leader for seven compounds that have entered human clinical trials. He has >135 scientific publications and 60 issued U.S. patents, and is the Editor-in-Chief of the journal Current Topics in Medicinal Chemistry. He is also Adjunct Professor at Drexel University College of Medicine, holds an Executive Masters in Technology Management from the University of Pennsylvania (Wharton, Penn Engineering), and is a Moore Fellow in the Management of Technology (U. Penn.).
Kathleen M. Shay
Kate is Intervir’s General counsel. She is a member of the Business Law section of the American Bar Association and the Corporation, Banking and Business Law section of the Pennsylvania Bar Association. She is former chair of the Executive Committee of the Business Law Section of the Philadelphia Bar Association and serves on the board of directors of the Philadelphia Chapter of the Association for Corporate Growth. She has extensive experience in representing companies of various sizes in stock financing, restructuring, venture capital financing and issuance of convertible notes and warrants. Ms. Shay has served on multiple boards including: MAC Alliance, Women Inventing Next, PA Biotechnology Association and the Technology Council of Eastern Pennsylvania as well as Villanova University, Academy of Notre Dame de Namur and the Delaware Valley Venture Group. She has published multiple papers on Biotechnology law and lectures numerous times annually on various life sciences issues. In 2010, she was awarded the prestigious Consultant of the Year. award by the Philadelphia Business Journal.